AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 271593 — intervention group
Group type: COMPARATOR
Intervention: Space-tufted brush
Number of subjects: 20
Study 29414244 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 0
Study 29414244 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 0
Study 27402145 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 125
Study 27402145 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 125
Study 24078055 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-T breast MRI
Number of subjects: 123
Study 24078055 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-T breast MRI in addition to conventional imaging
Number of subjects: 123
Study 22623617 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions for hand hygiene
Number of subjects: 16
Study 22623617 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 16
Study 20833596 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Girls Project intervention (4 weekly workshops with psychoeducational and behavioral components)
Number of subjects: 31
Study 20833596 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 31
Study 18801028 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1200 mg daily for 4 months)
Number of subjects: 144
Study 18801028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 15933496 — intervention group
Group type: EXPERIMENTAL
Intervention: Local corticosteroid injection
Number of subjects: 31
Study 15933496 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis
Number of subjects: 31
Study 15933496 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis
Number of subjects: 31
Study 12957702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation exercises
Number of subjects: 54
Study 12957702 — intervention group
Group type: COMPARATOR
Intervention: No cognitive intervention (control group)
Number of subjects: 54
Study 11116772 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-held shared care records
Number of subjects: 90
Study 9189040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (i.v.Ig) 0.4 gm/kg daily for either 3 days (n = 23) or 5 days (n = 23)
Number of subjects: 87
Study 9189040 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) 3 sessions
Number of subjects: 87
Study 9189040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (i.v.Ig)
Number of subjects: 87
Study 9189040 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange (PE)
Number of subjects: 87
Study 1443736 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA), n = 31
Number of subjects: 64
Study 1443736 — intervention group
Group type: COMPARATOR
Intervention: Face mask (control), n = 33
Number of subjects: 64
Study 1443736 — intervention group
Group type: COMPARATOR
Intervention: Face mask (control)
Number of subjects: 64
Study 1443736 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 64
Study 1443736 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) and Face mask (control)
Number of subjects: 64
Study 4022702 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based, lactose-free formula (group A)
Number of subjects: 87
Study 4022702 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (limited starvation, group B)
Number of subjects: 87
Study 29087781 — intervention group
Group type: EXPERIMENTAL
Intervention: VARIVAX™ New Seed Process (VARNSP)
Number of subjects: 0
Study 29087781 — intervention group
Group type: COMPARATOR
Intervention: Currently licensed VAR
Number of subjects: 0
Study 26769758 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 20
Study 26769758 — intervention group
Group type: COMPARATOR
Intervention: HHFNC
Number of subjects: 20
Study 24782199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg IV
Number of subjects: 100
Study 24782199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 32 mg IV
Number of subjects: 100
Study 24782199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg IV
Number of subjects: 100
Study 24782199 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 100
Study 24782199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 22691456 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction (DB group)
Number of subjects: 90
Study 22691456 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction with bioabsorbable screw fixation (SBB group)
Number of subjects: 90
Study 22691456 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction with metallic screw fixation (SBM group)
Number of subjects: 90
Study 22691456 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction (SBB group)
Number of subjects: 90
Study 22691456 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction (SBM group)
Number of subjects: 90
Study 22691456 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 20039806 — intervention group
Group type: EXPERIMENTAL
Intervention: DeltaNS1‐H1N1 A/New Caledonia vaccine at 1 of 5 dose levels (6.4, 6.7, 7.0, 7.4, and 7.7 log(10) median tissue culture infective dose)
Number of subjects: 48
Study 20039806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 20039806 — intervention group
Group type: EXPERIMENTAL
Intervention: DeltaNS1‐H1N1 A/New Caledonia vaccine
Number of subjects: 48
Study 18949297 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with distilled water (G1)
Number of subjects: 40
Study 18949297 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with polyethylene glycol (G2)
Number of subjects: 40
Study 18949297 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with polyethylene glycol + CMCP (G3)
Number of subjects: 40
Study 18949297 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with glycerin (G4)
Number of subjects: 40
Study 18949297 — intervention group
Group type: COMPARATOR
Intervention: Negative control (intact crowns)
Number of subjects: 40
Study 18949297 — intervention group
Group type: COMPARATOR
Intervention: Positive control (instrumented teeth without temporary dressing)
Number of subjects: 40
Study 15916468 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine (6 g/d for 6 weeks)
Number of subjects: 252
Study 15916468 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine (approximately 2.6 g/d of choline for 2 weeks)
Number of subjects: 252
Study 15916468 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg/d)
Number of subjects: 252
Study 15916468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 12456225 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic agents
Number of subjects: 461
Study 12456225 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 461
Study 10553160 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine alone (25 mg/m²/day for 5 days)
Number of subjects: 29
Study 10553160 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine and idarubicin (FLU-ID: fludarabine 25 mg/m² i.v. on days 1 to 3 and idarubicin 12 mg/m² i.v. on day 1)
Number of subjects: 29
Study 8635933 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer volume (VCa)
Number of subjects: 227
Study 8635933 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume fraction of the gland involved by carcinoma (VCafx)
Number of subjects: 227
Study 8635933 — intervention group
Group type: COMPARATOR
Intervention: PSA density
Number of subjects: 227
Study 8635933 — intervention group
Group type: COMPARATOR
Intervention: Cancer-specific PSA
Number of subjects: 227
Study 8635933 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated tumor volumes of < or = 0.5 cm3, 0.5-4.0 cm3, and > 4.0 cm3
Number of subjects: 227
Study 1733432 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (50 Gy with 2 Gy per fraction over 7 weeks)
Number of subjects: 468
Study 1733432 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy in high-risk patients
Number of subjects: 468
Study 6368889 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin-20 (20 mg/kg/dose for four days)
Number of subjects: 1877
Study 6368889 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin-10 (10 mg/kg/dose for two to four days)
Number of subjects: 1877
Study 6368889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1877
Study 6368889 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin-20 or Rifampin-10
Number of subjects: 1877
Study 6368889 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin-treated contacts
Number of subjects: 1877
Study 31730458 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR5 32 allele carriers
Number of subjects: 400
Study 29517695 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (n=27; combined ED95 rocuronium and ED95 cisatracurium)
Number of subjects: 81
Study 29517695 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S (n=27; dose reduced by 10% of each ED95)
Number of subjects: 81
Study 29517695 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L (n=27; dose reduced by 20% of each ED95)
Number of subjects: 81
Study 26581819 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended medication (26 weeks of nicotine patch + nicotine gum)
Number of subjects: 544
Study 26581819 — intervention group
Group type: COMPARATOR
Intervention: Extended medication (8 weeks of nicotine patch + nicotine gum)
Number of subjects: 544
Study 26581819 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance (phone) counseling
Number of subjects: 544
Study 26581819 — intervention group
Group type: COMPARATOR
Intervention: No maintenance counseling
Number of subjects: 544
Study 26581819 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence counseling
Number of subjects: 544
Study 26581819 — intervention group
Group type: COMPARATOR
Intervention: No medication adherence counseling
Number of subjects: 544
Study 26581819 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated (medication) adherence calls
Number of subjects: 544
Study 26581819 — intervention group
Group type: COMPARATOR
Intervention: No automated adherence calls
Number of subjects: 544
Study 26581819 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic medication monitoring with feedback and counseling
Number of subjects: 544
Study 26581819 — intervention group
Group type: COMPARATOR
Intervention: Electronic medication monitoring alone
Number of subjects: 544
Study 23787544 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol 1 μg/day
Number of subjects: 100
Study 23787544 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol 2 μg/day
Number of subjects: 100
Study 23787544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21558570 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin supplementation (500 mg of quercetin-3-glucoside, consumed twice a day, totaling 1,000 mg/d)
Number of subjects: 15
Study 21558570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 21558570 — intervention group
Group type: COMPARATOR
Intervention: 6% carbohydrate commercial sports drink
Number of subjects: 15
Study 21558570 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin supplementation
Number of subjects: 15
Study 19433274 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.05 mg, twice daily)
Number of subjects: 12
Study 19433274 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam (10 mg/kg/day, divided twice daily)
Number of subjects: 12
Study 19433274 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 12
Study 19433274 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam
Number of subjects: 12
Study 16430539 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 microg
Number of subjects: 84
Study 16430539 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 300 microg
Number of subjects: 84
Study 16430539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 16430539 — intervention group
Group type: COMPARATOR
Intervention: N2O with 5% sevoflurane
Number of subjects: 84
Study 15577771 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ventilation tube insertion and adenoidectomy
Number of subjects: 0
Study 15577771 — intervention group
Group type: COMPARATOR
Intervention: Control group (otherwise healthy children)
Number of subjects: 0
Study 11396392 — intervention group
Group type: EXPERIMENTAL
Intervention: ChromaGen contact lenses
Number of subjects: 14
Study 9268178 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinase
Number of subjects: 48
Study 9268178 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine sulfate
Number of subjects: 48
Study 9268178 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 48
Study 8491998 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary segments with diameter > 3 mm
Number of subjects: 348
Study 8491998 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary segments with diameter 2-3 mm
Number of subjects: 348
Study 8491998 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary segments with diameter < 2 mm
Number of subjects: 348
Study 8491998 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal coronary segments
Number of subjects: 348
Study 8491998 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid coronary segments
Number of subjects: 348
Study 8491998 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal coronary segments
Number of subjects: 348
Study 8491998 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal segments < 2 mm
Number of subjects: 348
Study 3301456 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 5
Study 3301456 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 5
Study 29648858 — intervention group
Group type: EXPERIMENTAL
Intervention: Alliance-focused training (AFT)
Number of subjects: 40
Study 27029450 — intervention group
Group type: EXPERIMENTAL
Intervention: Noophen 500 mg/day
Number of subjects: 58
Study 27029450 — intervention group
Group type: COMPARATOR
Intervention: Betahistin
Number of subjects: 58
Study 24493231 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin and metronidazole (AB) for 7 days
Number of subjects: 36
Study 24493231 — intervention group
Group type: COMPARATOR
Intervention: Antibacterial photodynamic therapy (aPDT) with two episodes
Number of subjects: 36
Study 22331154 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified supervised toothbrushing program (professional cross-brushing five times per year)
Number of subjects: 284
Study 22331154 — intervention group
Group type: COMPARATOR
Intervention: Conventional supervised toothbrushing program (oral health education and dental plaque dying followed by toothbrushing with fluoride dentifrice four times per year)
Number of subjects: 284
Study 21384736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment
Number of subjects: 34
Study 21384736 — intervention group
Group type: COMPARATOR
Intervention: Local corticosteroid injection plus splinting
Number of subjects: 34
Study 18834243 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD with calcium sulfate graft and membrane (CS)
Number of subjects: 51
Study 18834243 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD with collagen membrane (CM)
Number of subjects: 51
Study 18834243 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 51
Study 21178933 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg-1 bm)
Number of subjects: 10
Study 21178933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15781016 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol (group 1, n = 344)
Number of subjects: 689
Study 15781016 — intervention group
Group type: COMPARATOR
Intervention: clopidogrel (group 2, n = 345)
Number of subjects: 689
Study 11932866 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis fitted with TT Pylon (ProsWith)
Number of subjects: 6
Study 11932866 — intervention group
Group type: COMPARATOR
Intervention: Prosthesis without TT Pylon (ProsWithout)
Number of subjects: 6
Study 9610454 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic diclofenac sodium 50 mg given orally 1 hour before surgery
Number of subjects: 100
Study 9610454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diclofenac)
Number of subjects: 100
Study 7804666 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride (100 mg three times a day for at least one month)
Number of subjects: 100
Study 7804666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 3243926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ranitidine (50 mg over 5 minutes)
Number of subjects: 0
Study 3243926 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (not directly studied but referenced)
Number of subjects: 0
Study 11396641 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative techniques and promising new drugs for the treatment of advanced epithelial ovarian cancer
Number of subjects: 0
Study 30646291 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=196)
Number of subjects: 598
Study 30646291 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (n=143)
Number of subjects: 598
Study 30646291 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (n=128)
Number of subjects: 598
Study 30646291 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (n=131)
Number of subjects: 598
Study 27256816 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Lifestyle Physical Activity Program with 11 motivational interviewing personal calls (PCs)
Number of subjects: 0
Study 27256816 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Lifestyle Physical Activity Program with 11 automated motivational message calls (ACs)
Number of subjects: 0
Study 27256816 — intervention group
Group type: COMPARATOR
Intervention: Women's Lifestyle Physical Activity Program with no calls (Control)
Number of subjects: 0
Study 24829038 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized multidisciplinary tinnitus treatment based on cognitive behavioral therapy
Number of subjects: 492
Study 24829038 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 492
Study 23242019 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg intravenously twice a day for fasting time, then 40 mg orally twice a day until discharge
Number of subjects: 40
Study 23242019 — intervention group
Group type: COMPARATOR
Intervention: Non-pantoprazole (control group)
Number of subjects: 40
Study 20152243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin (10/20 mg) plus niacin (to 2 g)
Number of subjects: 942
Study 20152243 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe/simvastatin (10/20 mg)
Number of subjects: 942
Study 18817156 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1 mic kg(‐1) followed by 0.5 mic kg(‐1) min(‐1) i.v)
Number of subjects: 60
Study 18817156 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (20 mic kg(‐1) followed by 2 mic kg(‐1) min(‐1) i.v)
Number of subjects: 60
Study 18817156 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sciatic-femoral nerve block with ropivacaine 25 mL 0.75 mg
Number of subjects: 60
Study 18817156 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil and Alfentanil groups
Number of subjects: 60
Study 16105518 — intervention group
Group type: EXPERIMENTAL
Intervention: Practicing the entire task
Number of subjects: 0
Study 16105518 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice
Number of subjects: 0
Study 16105518 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice
Number of subjects: 0
Study 11978684 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 2420
Study 11978684 — intervention group
Group type: COMPARATOR
Intervention: Human insulin (HI)
Number of subjects: 2420
Study 10367507 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth I (BI)
Number of subjects: 45
Study 10367507 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth II (BII)
Number of subjects: 45
Study 10367507 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux en Y (Y)
Number of subjects: 45
Study 8775644 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐RPE trial
Number of subjects: 10
Study 8775644 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐RPE trial
Number of subjects: 10
Study 8775644 — intervention group
Group type: EXPERIMENTAL
Intervention: HR trial
Number of subjects: 10
Study 2279254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg t.i.d.) for 3 weeks
Number of subjects: 8
Study 2279254 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 8
Study 2279254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (300 mg daily for 3 weeks)
Number of subjects: 8
Study 2279254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 41542 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 14
Study 41542 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 14
Study 41542 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinalbarbitone 200 mg
Number of subjects: 14
Study 41542 — intervention group
Group type: COMPARATOR
Intervention: Temazepam 15 mg
Number of subjects: 14
Study 41542 — intervention group
Group type: COMPARATOR
Intervention: Flurazepam 15 mg
Number of subjects: 14
Study 41542 — intervention group
Group type: COMPARATOR
Intervention: Quinalbarbitone 100 mg
Number of subjects: 14
Study 41542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14